Tag Archives: Celldex Therapeutics

November, 2018

November, 2016

July, 2016

June, 2016

  • 6 June

    Celldex Presents Positive Results from its Phase II Melanoma Study

    HAMPTON, N.J., June 04, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDX‑1401 and CDX‑301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex …

April, 2016

March, 2016

  • 7 March

    Celldex Discontinues its Late-Stage Brain Cancer Vaccine Study

    HAMPTON, N.J., March 07, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma …

February, 2016

June, 2015

  • 1 June

    Celldex Vaccine Improves Survival in Patients with Deadly Brain Cancer

    Celldex Therapeutics presented results showing that its investigational cancer vaccine helped extend the lives of patients with a deadly form of brain cancer. The company presented results from the mid-stage trial evaluating Rintega (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual …